ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*广州中医药大学; 1
European Journal of Pharmacology2022-9-15DOI: 10.1016/j.ejphar.2022.175186
5被引11阅读
引用收藏
分享

摘要

Tumor chemoresistance is often a major cause for the failure of chemotherapy. The resistance of hepatocellular carcinoma (HCC) cells to sorafenib significantly limits its therapeutic effect in HCC patients. For the first time, we found that FXYD domain-containing ion transport regulator 5 (FXYD5) is highly expressed in sorafenib-resistant HCC cells. In addition, the protein expression level of FXYD5 was markedly higher in HCC tissues than in par-acancerous tissues. Remarkably, downregulation of FXYD5 expression in Huh7/sora cells reversed their resis-tance to sorafenib. Moreover, overexpression of FXYD5 reduced the sensitivity of HCC cells to sorafenib, while the downregulation of its expression in HCC cells had the opposite effect. We also found abnormal activation of the Akt/mTOR signaling pathway in Huh7/sora cells. Furthermore, MK2206, an Akt inhibitor, was found to significantly increase the sensitivity of HCC cells to sorafenib. More importantly, the expression level of p-Akt was positively correlated with the expression of FXYD5 in HCC tissues. Therefore, mechanistically, FXYD5 en-hances the resistance of HCC cells to sorafenib by activating the Akt/mTOR signaling pathway. In conclusion, this study showed that the activation of the FXYD5/Akt/mTOR signaling axis plays key role in the resistance of HCC cells to sorafenib, and FXYD5 may represent a new potential target for HCC therapy.

学科与关键词

关键词
HCCSorafenib resistanceFXYD5AktmTOR signaling pathway
相关
加载中…
  • ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
    Huang, Wenbin; Chen, Kunling; Lu, Yishi; Zhang, Donghui; Cheng, Yuan; Li, Liuran; Huang, Weimei; He, Guolin; Liao, Hangyu; Cai, Lei; Tang, Yujun; Zhao, Liang*; Pan, MingxinNeoplasia, 2021, 23(12): 1227-1239.被引 59
  • KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma
    Liu, Jia; Nie, Chunsheng*Anti-Cancer Drugs, 2022, 33(9): 840-849.被引 6
  • Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
    Luo, Jialiang; Li, Lei; Zhu, Zhengyumeng; Chang, Bo; Deng, Fan; Wang, Di; Lu, Xiao; Zuo, Daming; Chen, Qingyun*; Zhou, Jia*Biomedicine and Pharmacotherapy, 2022, 154: 113602.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Pharmacology
发表日期
2022-09-15
卷期
第 931 卷
页码
175186
DOI
10.1016/j.ejphar.2022.175186
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Youth Project of Education Department of Hunan Province [21B0365]; General Project of Hunan Health Commission [20200949]; Changsha Natural Science Foundation [KQ2202453]

作者

  • T

    Tan, Xiang-Peng (第一作者)

    1

  • X

    Xiong, Ben-Han

查看全部 6 位作者收起作者
  • Z

    Zhang, Yuan-Xu

  • W

    Wang, Shen-Li

  • Z

    Zuo, Qian (通讯)

    2 · guangzhou univ chinese med

  • L

    Li, Jing (通讯)

    1 · hunan univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417